ESMO: European Society for Medical Oncology

1. EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F)

   The benefit of this diagnostic radiopharmaceutical is its potential to diagnose prostate cancer during primary staging of patients at high risk and in the staging of patients with a suspected recurrence

2. Olaparib Plus Bevacizumab Provides Clinically Meaningful OS Improvement for Newly Diagnosed Patients with Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer

   Findings from the prespecified final overall survival analysis of the PAOLA-1/ENGOT-ov25 study

3. FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma

   Evidence for efficacy is based on the results from the EPCORE NHL-1 study

4. Significant PFS Benefit in Patients with HR-positive, HER2-negative MBC Who Switched Endocrine Treatment and Received Ribociclib After Previous CDK4/6 Inhibitor and Different Endocrine Therapy

   Findings from the MAINTAIN study

5. Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients with Cancer and HIV Even in Those on Antiretroviral Therapy

   Findings from the CATCH-IT Consortium study